title: Malignant mixed mullerian tumor of the uterus in a patient taking raloxifene.
abstract: BACKGROUND
  Uterine malignant mixed mesodermal tumor is a rare variant of uterine cancer. Data suggest that tamoxifen is involved in the pathogenesis. We report a case of a women in whom a malignant mixed mesodermal tumor was diagnosed while she was taking raloxifene, which is also a selective estrogen receptor modulator.
  
  
  METHODS
  A malignant mixed mesodermal tumor was diagnosed in a 64-year-old woman with a bicornuate uterus while she was taking raloxifene for osteoporosis prevention. Diagnosis had been delayed secondary to sampling of the other uterine horn.
  
  
  CONCLUSIONS
  There may be an association between raloxifene and the development of malignant mixed mesodermal tumor. Special attention should be paid when attempting to sample the endometrium in patients with mullerian abnormalities.
authors.affiliation: Department of Obstetrics and Gynecology and Women's Health, Division of Gynecologic Oncology, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York 10461, USA.
authors.forename: Noah A
authors.initials: NA
authors.lastname: Goldman
authors.forename: Maria M
authors.initials: MM
authors.lastname: de Los Angeles
authors.forename: Joan G
authors.initials: JG
authors.lastname: Jones
authors.forename: Gary L
authors.initials: GL
authors.lastname: Goldberg
mesh_terms: D001707:Biopsy, Needle; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007044:Hysterectomy / Q000379:methods; D007150:Immunohistochemistry; D008875:Middle Aged; D018200:Mixed Tumor, Mullerian / Q000139:chemically induced* / Q000473:pathology* / Q000628:therapy; D009367:Neoplasm Staging; D015663:Osteoporosis, Postmenopausal / Q000175:diagnosis / Q000188:drug therapy; D010052:Ovariectomy / Q000379:methods; D018714:Radiotherapy, Adjuvant; D020849:Raloxifene Hydrochloride / Q000009:adverse effects* / Q000627:therapeutic use; D020845:Selective Estrogen Receptor Modulators / Q000009:adverse effects* / Q000627:therapeutic use; D016896:Treatment Outcome; D014594:Uterine Neoplasms / Q000139:chemically induced* / Q000473:pathology* / Q000628:therapy
chemical_list: D020845:Selective Estrogen Receptor Modulators; D020849:Raloxifene Hydrochloride